Yu Bo, Xin Muyao, Sun Yu, Li Junran, Pazo Emmanuel Eric, Xing Xiaoli
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Present Address: Tianjin Medical University Eye Hospital, No. 251, Fukang Road, Nankai District, Tianjin, 300384, China.
BMC Ophthalmol. 2025 Aug 19;25(1):474. doi: 10.1186/s12886-025-04310-6.
To evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation in treating refractory glaucoma and analyze the factors influencing the surgical success rate.
A 3-year retrospective analysis was conducted on 199 patients with refractory glaucoma treated with AGV, model FP7.Preoperative and postoperative data, including intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical outcomes, were analyzed. Complete success was defined as an IOP ≤ 21 mmHg without the use of glaucoma medications or additional filtration surgery, and a reduction in IOP of ≥ 15% from baseline. The qualified success was defined as: IOP ≤ 21 mmHg with adjunctive medications or the reduction of IOP < 15% from baseline. The overall success encompassed both complete success and qualified success.
Complete Success rates were 60.5% and 56% at years 1 and 3, respectively. Overall success rates were 83% and 74.7% at the same intervals. Visual acuity (VA) showed statistically significant improvement at year 1 (P < 0.05), but changes at year 3 were not significant (P > 0.05). Low preoperative IOP and a history of pan-retinal photocoagulation (PRP) were identified as protective factors contributing to the success of surgical outcomes at year 1.
AGV implantation is a safe and effective treatment for neovascular glaucoma. Preoperative IOP and a history of PRP significantly influence surgical success at one year, with success rates declining over 3 years. Careful surgical execution is crucial for achieving optimal outcomes.
This retrospective study was registered in Chinese Clinical Trial Register (ChiCTR2400089879).
评估Ahmed青光眼引流阀（AGV）植入术治疗难治性青光眼的疗效，并分析影响手术成功率的因素。
对199例接受FP7型AGV治疗的难治性青光眼患者进行了为期3年的回顾性分析。分析术前和术后数据，包括眼压（IOP）、视力、青光眼药物使用数量和手术结果。完全成功定义为眼压≤21 mmHg，无需使用青光眼药物或额外的滤过手术，且眼压较基线降低≥15%。合格成功定义为：使用辅助药物时眼压≤21 mmHg，或眼压较基线降低<15%。总体成功包括完全成功和合格成功。
第1年和第3年的完全成功率分别为60.5%和56%。相同时间段的总体成功率分别为83%和74.7%。视力（VA）在第1年有统计学显著改善（P<0.05），但第3年的变化不显著（P>0.05）。术前低眼压和全视网膜光凝（PRP）病史被确定为第1年手术成功的保护因素。
AGV植入术是治疗新生血管性青光眼的一种安全有效的方法。术前眼压和PRP病史在1年内对手术成功有显著影响，成功率在3年内下降。谨慎的手术操作对于取得最佳结果至关重要。
本回顾性研究已在中国临床试验注册中心注册（ChiCTR2400089879）。
